LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors...
- Mechanism
- Curator reviewed
LY2275796 targets eIF-4E, a protein that is upregulated or overexpressed in a variety of cancers, including breast, head and neck, prostate, lung, bladder, colon, thyroid and non-Hodgkin's lymphomas. The molecule facilitates the synthesis of tumor angiogenic factors (factors that facilitate the growth of new blood vessels to support the development and progression of tumors), growth factors and survival factors by selectively enhancing their translation. Based on scientific literature, there is a strong indication that eIF-4E may act as a critical "switch" in cancer progression.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.Curator reviewed
- Code names
- LY2275796
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with LY2275796, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account